218 related articles for article (PubMed ID: 33525712)
1. Dual Tracer 68Ga-DOTATOC and 18F-FDG PET Improve Preoperative Evaluation of Aggressiveness in Resectable Pancreatic Neuroendocrine Neoplasms.
Mapelli P; Partelli S; Salgarello M; Doraku J; Muffatti F; Schiavo Lena M; Pasetto S; Bezzi C; Bettinardi V; Andreasi V; Rancoita PMV; Gianolli L; Picchio M; Falconi M
Diagnostics (Basel); 2021 Jan; 11(2):. PubMed ID: 33525712
[TBL] [Abstract][Full Text] [Related]
2. Dual tracer 68Ga-DOTATOC and 18F-FDG PET/computed tomography radiomics in pancreatic neuroendocrine neoplasms: an endearing tool for preoperative risk assessment.
Mapelli P; Partelli S; Salgarello M; Doraku J; Pasetto S; Rancoita PMV; Muffatti F; Bettinardi V; Presotto L; Andreasi V; Gianolli L; Picchio M; Falconi M
Nucl Med Commun; 2020 Sep; 41(9):896-905. PubMed ID: 32796478
[TBL] [Abstract][Full Text] [Related]
3. Dual-Tracer (68Ga-DOTATOC and 18F-FDG-)-PET/CT Scan and G1-G2 Nonfunctioning Pancreatic Neuroendocrine Tumors: A Single-Center Retrospective Evaluation of 124 Nonmetastatic Resected Cases.
Paiella S; Landoni L; Tebaldi S; Zuffante M; Salgarello M; Cingarlini S; D'Onofrio M; Parisi A; Deiro G; Manfrin E; Bianchi B; Montagnini G; Crinò SF; Bassi C; Salvia R
Neuroendocrinology; 2022; 112(2):143-152. PubMed ID: 33508821
[TBL] [Abstract][Full Text] [Related]
4.
Mapelli P; Bezzi C; Palumbo D; Canevari C; Ghezzo S; Samanes Gajate AM; Catalfamo B; Messina A; Presotto L; Guarnaccia A; Bettinardi V; Muffatti F; Andreasi V; Schiavo Lena M; Gianolli L; Partelli S; Falconi M; Scifo P; De Cobelli F; Picchio M
Eur J Nucl Med Mol Imaging; 2022 Jun; 49(7):2352-2363. PubMed ID: 35156146
[TBL] [Abstract][Full Text] [Related]
5. The potential application of MR-derived ADCmin values from
Gao J; Xu S; Ju H; Pan Y; Zhang Y
EJNMMI Res; 2023 Feb; 13(1):10. PubMed ID: 36752942
[TBL] [Abstract][Full Text] [Related]
6. Combined imaging with 68Ga-DOTA-TATE and 18F-FDG PET/CT on the basis of volumetric parameters in neuroendocrine tumors.
Abdulrezzak U; Kurt YK; Kula M; Tutus A
Nucl Med Commun; 2016 Aug; 37(8):874-81. PubMed ID: 27096719
[TBL] [Abstract][Full Text] [Related]
7. Comparison of 68Ga-DOTANOC and 18F-FDG PET-CT Scans in the Evaluation of Primary Tumors and Lymph Node Metastasis in Patients With Rectal Neuroendocrine Tumors.
Zhou Z; Wang Z; Zhang B; Wu Y; Li G; Wang Z
Front Endocrinol (Lausanne); 2021; 12():727327. PubMed ID: 34539577
[TBL] [Abstract][Full Text] [Related]
8. Somatostatin receptor activity assessed by
Mapelli P; Bezzi C; Muffatti F; Ghezzo S; Baldassi F; Schiavo Lena M; Andreasi V; Canevari C; Magnani P; De Cobelli F; Gianolli L; Partelli S; Falconi M; Picchio M
Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2818-2829. PubMed ID: 37010579
[TBL] [Abstract][Full Text] [Related]
9. Optimal FDG PET/CT volumetric parameters for risk stratification in patients with locally advanced non-small cell lung cancer: results from the ACRIN 6668/RTOG 0235 trial.
Salavati A; Duan F; Snyder BS; Wei B; Houshmand S; Khiewvan B; Opanowski A; Simone CB; Siegel BA; Machtay M; Alavi A
Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):1969-1983. PubMed ID: 28689281
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Value of Volumetric Parameters Measured by Pretreatment 18F FDG PET/CT in Patients With Cutaneous Malignant Melanoma.
Son SH; Kang SM; Jeong SY; Lee SW; Lee SJ; Lee J; Ahn BC
Clin Nucl Med; 2016 Jun; 41(6):e266-73. PubMed ID: 27055144
[TBL] [Abstract][Full Text] [Related]
11. Value of [
Deleu AL; Laenen A; Decaluwé H; Weynand B; Dooms C; De Wever W; Jentjens S; Goffin K; Vansteenkiste J; Van Laere K; De Leyn P; Nackaerts K; Deroose CM
EJNMMI Res; 2022 May; 12(1):28. PubMed ID: 35524900
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the pharmacokinetics of 68Ga-DOTATOC and [18F]FDG in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy.
Koukouraki S; Strauss LG; Georgoulias V; Eisenhut M; Haberkorn U; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2006 Oct; 33(10):1115-22. PubMed ID: 16763820
[TBL] [Abstract][Full Text] [Related]
13. Assessment of Mediastinal Tumors Using SUV
Morita T; Tatsumi M; Ishibashi M; Isohashi K; Kato H; Honda O; Shimosegawa E; Tomiyama N; Hatazawa J
Asia Ocean J Nucl Med Biol; 2017; 5(1):22-29. PubMed ID: 28840135
[TBL] [Abstract][Full Text] [Related]
14. Metabolic Tumor Volume on 18F-FDG PET/CT Improves Preoperative Identification of High-Risk Endometrial Carcinoma Patients.
Husby JA; Reitan BC; Biermann M; Trovik J; Bjørge L; Magnussen IJ; Salvesen ØO; Salvesen HB; Haldorsen IS
J Nucl Med; 2015 Aug; 56(8):1191-8. PubMed ID: 26045311
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis on Preoperative ¹⁸F-FDG PET/CT in Patients with Pancreatic Cancer.
Lee JW; Kang CM; Choi HJ; Lee WJ; Song SY; Lee JH; Lee JD
J Nucl Med; 2014 Jun; 55(6):898-904. PubMed ID: 24711649
[TBL] [Abstract][Full Text] [Related]
16. Preoperative characterization of indeterminate large adrenal masses with dual tracer PET-CT using fluorine-18 fluorodeoxyglucose and gallium-68-DOTANOC: initial results.
Naswa N; Sharma P; Soundararajan R; Patnecha M; Lata S; Kumar R; Malhotra A; Bal C
Diagn Interv Radiol; 2013; 19(4):294-8. PubMed ID: 23439252
[TBL] [Abstract][Full Text] [Related]
17. 68Ga-DOTATOC and 18F-FDG PET/CT for identifying the primary lesions of suspected and metastatic neuroendocrine tumors: A prospective study in Taiwan.
Chen SH; Chang YC; Hwang TL; Chen JS; Chou WC; Hsieh CH; Yeh TS; Hsu JT; Yeh CN; Tseng JH; Chen TC; Yen TC
J Formos Med Assoc; 2018 Jun; 117(6):480-487. PubMed ID: 28735662
[TBL] [Abstract][Full Text] [Related]
18. Role of PET/CT and Therapy Management of Pancreatic Neuroendocrine Tumors.
Calabrò D; Argalia G; Ambrosini V
Diagnostics (Basel); 2020 Dec; 10(12):. PubMed ID: 33297381
[TBL] [Abstract][Full Text] [Related]
19. The value of different
Anwar H; Vogl TJ; Abougabal MA; Grünwald F; Kleine P; Elrefaie S; Nour-Eldin NA
Ann Nucl Med; 2018 Dec; 32(10):687-694. PubMed ID: 30219989
[TBL] [Abstract][Full Text] [Related]
20. Comparison of 18F-DOPA Versus 68Ga-DOTATOC as Preferred PET Imaging Tracer in Well-Differentiated Neuroendocrine Neoplasms.
Veenstra EB; de Groot DJA; Brouwers AH; Walenkamp AME; Noordzij W
Clin Nucl Med; 2021 Mar; 46(3):195-200. PubMed ID: 33323729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
